Global In Vivo Pharmacology Service 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI08244043

Publication Date:

August 7, 2024

Pages:

131

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

In vivo pharmacology is a critical stage in drug discovery that involves testing new drugs in living organisms to evaluate their efficacy, safety, and pharmacokinetics. In vivo studies provide valuable insights into your drug's interactions with the body, including its metabolism, absorption, distribution, and excretion. In vivo pharmacology also helps researcher identify potential side effects, determine optimal dosing regimens, and assess the drug's overall therapeutic potential.In vivo pharmacology involves studying the effects of drugs within living organisms, providing insights into their behavior, efficacy, and safety, including absorption, distribution, metabolism, and pharmacodynamics, key to the preclinical drug discovery and development process.
The global In Vivo Pharmacology Service market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淚n Vivo Pharmacology Service Industry Forecast鈥� looks at past sales and reviews total world In Vivo Pharmacology Service sales in 2022, providing a comprehensive analysis by region and market sector of projected In Vivo Pharmacology Service sales for 2023 through 2029. With In Vivo Pharmacology Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world In Vivo Pharmacology Service industry.
This Insight Report provides a comprehensive analysis of the global In Vivo Pharmacology Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on In Vivo Pharmacology Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global In Vivo Pharmacology Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for In Vivo Pharmacology Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global In Vivo Pharmacology Service.
United States market for In Vivo Pharmacology Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for In Vivo Pharmacology Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for In Vivo Pharmacology Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key In Vivo Pharmacology Service players cover NuChem Sciences Inc, Eurofins Discovery, Oncodesign Services, Jubilant Biosys, Pharmaron, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of In Vivo Pharmacology Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Small Molecule Screening
Large Molecule Screening
Others
Segmentation by Application:
Neurological Diseases
Cardiovascular and Metabolic Diseases
Skin Diseases
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Small Molecule Screening
Large Molecule Screening
Others
Segmentation by Application:
Neurological Diseases
Cardiovascular and Metabolic Diseases
Skin Diseases
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
NuChem Sciences Inc
Eurofins Discovery
Oncodesign Services
Jubilant Biosys
Pharmaron
Melior Discovery
NUVISAN GmbH
Porsolt
Sygnature Discovery
Aurigene Pharmaceutical Services Ltd
Reaction Biology
Addexbio
Paraza Pharma, Inc
Aragen Life Sciences Ltd
Dalriada
Biocytogen
Charles River Laboratories
Pharmacelsu
HitGen Inc
TCG Lifesciences

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global In Vivo Pharmacology Service 麻豆原创 Size 2019-2030
2.1.2 In Vivo Pharmacology Service 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for In Vivo Pharmacology Service by Country/Region, 2019, 2023 & 2030
2.2 In Vivo Pharmacology Service Segment by Type
2.2.1 Small Molecule Screening
2.2.2 Large Molecule Screening
2.2.3 Others
2.3 In Vivo Pharmacology Service 麻豆原创 Size by Type
2.3.1 In Vivo Pharmacology Service 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global In Vivo Pharmacology Service 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 In Vivo Pharmacology Service Segment by Application
2.4.1 Neurological Diseases
2.4.2 Cardiovascular and Metabolic Diseases
2.4.3 Skin Diseases
2.4.4 Others
2.5 In Vivo Pharmacology Service 麻豆原创 Size by Application
2.5.1 In Vivo Pharmacology Service 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global In Vivo Pharmacology Service 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 In Vivo Pharmacology Service 麻豆原创 Size by Player
3.1 In Vivo Pharmacology Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global In Vivo Pharmacology Service Revenue by Player (2019-2024)
3.1.2 Global In Vivo Pharmacology Service Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global In Vivo Pharmacology Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 In Vivo Pharmacology Service by Region
4.1 In Vivo Pharmacology Service 麻豆原创 Size by Region (2019-2024)
4.2 Global In Vivo Pharmacology Service Annual Revenue by Country/Region (2019-2024)
4.3 Americas In Vivo Pharmacology Service 麻豆原创 Size Growth (2019-2024)
4.4 APAC In Vivo Pharmacology Service 麻豆原创 Size Growth (2019-2024)
4.5 Europe In Vivo Pharmacology Service 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa In Vivo Pharmacology Service 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas In Vivo Pharmacology Service 麻豆原创 Size by Country (2019-2024)
5.2 Americas In Vivo Pharmacology Service 麻豆原创 Size by Type (2019-2024)
5.3 Americas In Vivo Pharmacology Service 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC In Vivo Pharmacology Service 麻豆原创 Size by Region (2019-2024)
6.2 APAC In Vivo Pharmacology Service 麻豆原创 Size by Type (2019-2024)
6.3 APAC In Vivo Pharmacology Service 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe In Vivo Pharmacology Service 麻豆原创 Size by Country (2019-2024)
7.2 Europe In Vivo Pharmacology Service 麻豆原创 Size by Type (2019-2024)
7.3 Europe In Vivo Pharmacology Service 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa In Vivo Pharmacology Service by Region (2019-2024)
8.2 Middle East & Africa In Vivo Pharmacology Service 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa In Vivo Pharmacology Service 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global In Vivo Pharmacology Service 麻豆原创 Forecast
10.1 Global In Vivo Pharmacology Service Forecast by Region (2025-2030)
10.1.1 Global In Vivo Pharmacology Service Forecast by Region (2025-2030)
10.1.2 Americas In Vivo Pharmacology Service Forecast
10.1.3 APAC In Vivo Pharmacology Service Forecast
10.1.4 Europe In Vivo Pharmacology Service Forecast
10.1.5 Middle East & Africa In Vivo Pharmacology Service Forecast
10.2 Americas In Vivo Pharmacology Service Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 In Vivo Pharmacology Service Forecast
10.2.2 Canada 麻豆原创 In Vivo Pharmacology Service Forecast
10.2.3 Mexico 麻豆原创 In Vivo Pharmacology Service Forecast
10.2.4 Brazil 麻豆原创 In Vivo Pharmacology Service Forecast
10.3 APAC In Vivo Pharmacology Service Forecast by Region (2025-2030)
10.3.1 China In Vivo Pharmacology Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 In Vivo Pharmacology Service Forecast
10.3.3 Korea 麻豆原创 In Vivo Pharmacology Service Forecast
10.3.4 Southeast Asia 麻豆原创 In Vivo Pharmacology Service Forecast
10.3.5 India 麻豆原创 In Vivo Pharmacology Service Forecast
10.3.6 Australia 麻豆原创 In Vivo Pharmacology Service Forecast
10.4 Europe In Vivo Pharmacology Service Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 In Vivo Pharmacology Service Forecast
10.4.2 France 麻豆原创 In Vivo Pharmacology Service Forecast
10.4.3 UK 麻豆原创 In Vivo Pharmacology Service Forecast
10.4.4 Italy 麻豆原创 In Vivo Pharmacology Service Forecast
10.4.5 Russia 麻豆原创 In Vivo Pharmacology Service Forecast
10.5 Middle East & Africa In Vivo Pharmacology Service Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 In Vivo Pharmacology Service Forecast
10.5.2 South Africa 麻豆原创 In Vivo Pharmacology Service Forecast
10.5.3 Israel 麻豆原创 In Vivo Pharmacology Service Forecast
10.5.4 Turkey 麻豆原创 In Vivo Pharmacology Service Forecast
10.6 Global In Vivo Pharmacology Service Forecast by Type (2025-2030)
10.7 Global In Vivo Pharmacology Service Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 In Vivo Pharmacology Service Forecast
11 Key Players Analysis
11.1 NuChem Sciences Inc
11.1.1 NuChem Sciences Inc Company Information
11.1.2 NuChem Sciences Inc In Vivo Pharmacology Service Product Offered
11.1.3 NuChem Sciences Inc In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 NuChem Sciences Inc Main Business Overview
11.1.5 NuChem Sciences Inc Latest Developments
11.2 Eurofins Discovery
11.2.1 Eurofins Discovery Company Information
11.2.2 Eurofins Discovery In Vivo Pharmacology Service Product Offered
11.2.3 Eurofins Discovery In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Eurofins Discovery Main Business Overview
11.2.5 Eurofins Discovery Latest Developments
11.3 Oncodesign Services
11.3.1 Oncodesign Services Company Information
11.3.2 Oncodesign Services In Vivo Pharmacology Service Product Offered
11.3.3 Oncodesign Services In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Oncodesign Services Main Business Overview
11.3.5 Oncodesign Services Latest Developments
11.4 Jubilant Biosys
11.4.1 Jubilant Biosys Company Information
11.4.2 Jubilant Biosys In Vivo Pharmacology Service Product Offered
11.4.3 Jubilant Biosys In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Jubilant Biosys Main Business Overview
11.4.5 Jubilant Biosys Latest Developments
11.5 Pharmaron
11.5.1 Pharmaron Company Information
11.5.2 Pharmaron In Vivo Pharmacology Service Product Offered
11.5.3 Pharmaron In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Pharmaron Main Business Overview
11.5.5 Pharmaron Latest Developments
11.6 Melior Discovery
11.6.1 Melior Discovery Company Information
11.6.2 Melior Discovery In Vivo Pharmacology Service Product Offered
11.6.3 Melior Discovery In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Melior Discovery Main Business Overview
11.6.5 Melior Discovery Latest Developments
11.7 NUVISAN GmbH
11.7.1 NUVISAN GmbH Company Information
11.7.2 NUVISAN GmbH In Vivo Pharmacology Service Product Offered
11.7.3 NUVISAN GmbH In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 NUVISAN GmbH Main Business Overview
11.7.5 NUVISAN GmbH Latest Developments
11.8 Porsolt
11.8.1 Porsolt Company Information
11.8.2 Porsolt In Vivo Pharmacology Service Product Offered
11.8.3 Porsolt In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Porsolt Main Business Overview
11.8.5 Porsolt Latest Developments
11.9 Sygnature Discovery
11.9.1 Sygnature Discovery Company Information
11.9.2 Sygnature Discovery In Vivo Pharmacology Service Product Offered
11.9.3 Sygnature Discovery In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Sygnature Discovery Main Business Overview
11.9.5 Sygnature Discovery Latest Developments
11.10 Aurigene Pharmaceutical Services Ltd
11.10.1 Aurigene Pharmaceutical Services Ltd Company Information
11.10.2 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Service Product Offered
11.10.3 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Aurigene Pharmaceutical Services Ltd Main Business Overview
11.10.5 Aurigene Pharmaceutical Services Ltd Latest Developments
11.11 Reaction Biology
11.11.1 Reaction Biology Company Information
11.11.2 Reaction Biology In Vivo Pharmacology Service Product Offered
11.11.3 Reaction Biology In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Reaction Biology Main Business Overview
11.11.5 Reaction Biology Latest Developments
11.12 Addexbio
11.12.1 Addexbio Company Information
11.12.2 Addexbio In Vivo Pharmacology Service Product Offered
11.12.3 Addexbio In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Addexbio Main Business Overview
11.12.5 Addexbio Latest Developments
11.13 Paraza Pharma, Inc
11.13.1 Paraza Pharma, Inc Company Information
11.13.2 Paraza Pharma, Inc In Vivo Pharmacology Service Product Offered
11.13.3 Paraza Pharma, Inc In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Paraza Pharma, Inc Main Business Overview
11.13.5 Paraza Pharma, Inc Latest Developments
11.14 Aragen Life Sciences Ltd
11.14.1 Aragen Life Sciences Ltd Company Information
11.14.2 Aragen Life Sciences Ltd In Vivo Pharmacology Service Product Offered
11.14.3 Aragen Life Sciences Ltd In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Aragen Life Sciences Ltd Main Business Overview
11.14.5 Aragen Life Sciences Ltd Latest Developments
11.15 Dalriada
11.15.1 Dalriada Company Information
11.15.2 Dalriada In Vivo Pharmacology Service Product Offered
11.15.3 Dalriada In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Dalriada Main Business Overview
11.15.5 Dalriada Latest Developments
11.16 Biocytogen
11.16.1 Biocytogen Company Information
11.16.2 Biocytogen In Vivo Pharmacology Service Product Offered
11.16.3 Biocytogen In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Biocytogen Main Business Overview
11.16.5 Biocytogen Latest Developments
11.17 Charles River Laboratories
11.17.1 Charles River Laboratories Company Information
11.17.2 Charles River Laboratories In Vivo Pharmacology Service Product Offered
11.17.3 Charles River Laboratories In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Charles River Laboratories Main Business Overview
11.17.5 Charles River Laboratories Latest Developments
11.18 Pharmacelsu
11.18.1 Pharmacelsu Company Information
11.18.2 Pharmacelsu In Vivo Pharmacology Service Product Offered
11.18.3 Pharmacelsu In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Pharmacelsu Main Business Overview
11.18.5 Pharmacelsu Latest Developments
11.19 HitGen Inc
11.19.1 HitGen Inc Company Information
11.19.2 HitGen Inc In Vivo Pharmacology Service Product Offered
11.19.3 HitGen Inc In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 HitGen Inc Main Business Overview
11.19.5 HitGen Inc Latest Developments
11.20 TCG Lifesciences
11.20.1 TCG Lifesciences Company Information
11.20.2 TCG Lifesciences In Vivo Pharmacology Service Product Offered
11.20.3 TCG Lifesciences In Vivo Pharmacology Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 TCG Lifesciences Main Business Overview
11.20.5 TCG Lifesciences Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.